医学
米诺地尔
脱发
社会心理的
耐受性
皮肤病科
卵泡期
更年期
析因分析
生活质量(医疗保健)
临床试验
绝经后妇女
随机对照试验
加药
妇科
内科学
疾病
雌激素
斑秃
年轻人
临床研究
观察研究
生理学
毛发生长
作者
Ramond J. Waide,Hsiao-Pin Liu,Asha Patel Shah,Payvand Kamrani,Deirdre Hooper,Nicole E. Rogers
标识
DOI:10.1097/dss.0000000000005472
摘要
BACKGROUND: Female pattern hair loss (FPHL) affects up to 50% of women and becomes increasingly prevalent after menopause. Declining estrogen levels, altered hormonal balance, and follicular miniaturization contribute to disease progression, which can substantially impair quality of life (QoL). OBJECTIVE: The aim of this study was to review the pathophysiology and psychosocial impact of FPHL, discuss patient counseling and treatment expectations, and evaluate the benefits of topical minoxidil in postmenopausal women. METHODS: Published evidence on FPHL pathophysiology, psychosocial outcomes, treatment barriers, and minoxidil efficacy and tolerability was searched for online using Google and via PubMed. Publications were reviewed for relevance based on the objectives as listed above before being selected for inclusion in our narrative. Findings from a post hoc subgroup analysis of postmenopausal women in a phase III clinical trial of once-daily 5% minoxidil topical foam (MTF) were also assessed. RESULTS: FPHL is influenced by genetic susceptibility, aging, and menopausal hormonal changes. Hair loss is associated with reduced self-esteem, social withdrawal, anxiety, and impaired QoL. Delayed treatment initiation is common. In a phase III study, 5% MTF significantly increased hair count versus vehicle at 24 weeks. Post hoc analyses demonstrated significant hair regrowth in postmenopausal women with both early and advanced hair loss. CONCLUSION: Once-daily 5% MTF is effective in postmenopausal women regardless of disease severity. Early recognition, patient education, individualized treatment selection, and psychosocial support are essential for optimal outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI